Diligence memo · auto-generated · as of July 2, 2026
Biohaven Pharmaceutical Holding Co Ltd.
Biohaven Pharmaceutical Holding Co Ltd. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Biohaven Pharmaceutical Holding Co Ltd. operates in Pharmaceuticals, based in New Haven.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biohaven Pharmaceutical Holding Co Ltd. has raised $40M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $40M on 2016-10-31.
Most recent recorded round closed around 2016-10-31.
Valuation (modeled)modeled
Provath models Biohaven Pharmaceutical Holding Co Ltd. at approximately $1.4B (range $130M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.60× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 9.7 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 78% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.